Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
SingaporeIPO:
11 November 2015Website:
http://www.wavelifesciences.comNext earnings report:
06 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 23:46:24 GMTDividend
Analysts recommendations
Institutional Ownership
WVE Latest News
CAMBRIDGE, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:30 p.m. GMT / 11:30 a.m. ET.
Wave Life Sciences Ltd. (NASDAQ:WVE ) Q3 2024 Results Conference Call November 12, 2024 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - Chief Financial Officer Conference Call Participants Steven Seedhouse - Raymond James Joon Lee - Truist Salim Syed - Mizuho Luca Issi - RBC Catherine Novack - Jones Trading Madison El-Saadi - B.
Wave Life Sciences (WVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This stock currently has a good balance of risk and potential rewards.
Does Wave Life Sciences (WVE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wave Life Sciences Ltd. NASDAQ: WVE is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health.
Wave Life Sciences' stock soars on positive initial data showing the first-ever therapeutic RNA editing in humans in the phase Ib/IIa study of WVE-006 for AATD.
Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Wave Life Sciences announced positive results from its phase 1b/2a RestorAAtion-2 study using WVE-006 for the treatment of alpha-1 antitrypsin deficiency patients. A single subcutaneous administration of 200 mg of WVE-006 resulted in the presence of wild-type alpha-1 antitrypsin protein; This led to a more than 60% increase of AAT. The global Alpha-1 Antitrypsin Deficiency market is expected to reach a $10 billion market value by 2033.
Event will highlight WVE-006 for AATD and Wave's rapidly advancing, wholly owned pipeline of RNA medicines, including introducing new RNA editing programs and new preclinical data for WVE-007 INHBE program for obesity Event will highlight WVE-006 for AATD and Wave's rapidly advancing, wholly owned pipeline of RNA medicines, including introducing new RNA editing programs and new preclinical data for WVE-007 INHBE program for obesity
- 1(current)
- 2
What type of business is Wave Life Sciences?
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
What sector is Wave Life Sciences in?
Wave Life Sciences is in the Healthcare sector
What industry is Wave Life Sciences in?
Wave Life Sciences is in the Biotechnology industry
What country is Wave Life Sciences from?
Wave Life Sciences is headquartered in Singapore
When did Wave Life Sciences go public?
Wave Life Sciences initial public offering (IPO) was on 11 November 2015
What is Wave Life Sciences website?
https://www.wavelifesciences.com
Is Wave Life Sciences in the S&P 500?
No, Wave Life Sciences is not included in the S&P 500 index
Is Wave Life Sciences in the NASDAQ 100?
No, Wave Life Sciences is not included in the NASDAQ 100 index
Is Wave Life Sciences in the Dow Jones?
No, Wave Life Sciences is not included in the Dow Jones index
When was Wave Life Sciences the previous earnings report?
No data
When does Wave Life Sciences earnings report?
The next expected earnings date for Wave Life Sciences is 06 March 2025